ESCO2 Antibody - BSA Free

Western Blot: ESCO2 Antibody - BSA Free [NB100-87021] -

Molecular mechanisms of ESCO2 in regulating cell cycle and apoptosis. (A) Western blots showing alterations in p53, p-p53, p21 and BAX expression with ESCO2 knockdown. (B) Western blots showing alterations in CDK1 and cyclin B1 expression with ESCO2 knockdown. (C) Western blot analysis of Bcl-2, caspase-9, and caspase-7 expression and activation following ESCO2 knockdown. (D) Co-IP assays were performed using anti-ESCO2 antibody or IgG control. (E) Co-IP assays were performed using anti-CDK1 antibody or IgG control. (F, G) Quantitative analysis of protein expression (n=3, unpaired t test). (ns: p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Image collected and cropped by CiteAb from the following open publication (https://www.frontiersin.org/articles/10.3389/fonc.2025.1585945/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ESCO2 Antibody - BSA Free [NB100-87021] -

Molecular mechanisms of ESCO2 in regulating cell cycle and apoptosis. (A) Western blots showing alterations in p53, p-p53, p21 and BAX expression with ESCO2 knockdown. (B) Western blots showing alterations in CDK1 and cyclin B1 expression with ESCO2 knockdown. (C) Western blot analysis of Bcl-2, caspase-9, and caspase-7 expression and activation following ESCO2 knockdown. (D) Co-IP assays were performed using anti-ESCO2 antibody or IgG control. (E) Co-IP assays were performed using anti-CDK1 antibody or IgG control. (F, G) Quantitative analysis of protein expression (n=3, unpaired t test). (ns: p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Image collected and cropped by CiteAb from the following open publication (https://www.frontiersin.org/articles/10.3389/fonc.2025.1585945/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ESCO2 Antibody - BSA Free [NB100-87021] -

Identification of Proteome Changes Conserved Between Human and Primate Lentiviral Vpr Lineages(A) Graphical summary of the TMT experiment testing conservation of Vpr function.(B) GFP+ (transduced) cells at harvest. Cells were transduced at an infectious MOI of 1.5 based on prior titration, with the actual resulting percent transduction varying slightly across the samples. Because non-HIV-1/SIVcpz Vpr is not packaged in the viral particles used, the percent transduced represents all cells exposed to Vpr under those conditions.(C) Proportion of cells in G2/M at point of harvest, based on 7-AAD staining and Watson pragmatic modeling.(D) Scatterplots showing the pairwise comparison between each Vpr tested and empty vector control, with defined groups of 302 Vpr-depleted (blue) and 413 increased (red) proteins highlighted.(E) Immunoblot of example known, non-conserved, and conserved targets of Vpr-mediated depletion. The HIV-2 Vpr is a primary isolate HIV-2 Vpr (7312a), whereas the proteomics experiment described in (A) used HIV-2 ROD Vpr. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31042482), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ESCO2 Antibody - BSA Free [NB100-87021] -

Overexpression of ESCO2 promotes DNA replication. (A, B) Validation of lentiviral transfection efficiency for ESCO2 overexpression via qRT-PCR in MDA-MB-231 and MDA-MB-468 cells (n=3, One-way ANOVA). (C-E) Validation of lentiviral transfection efficiency for ESCO2 overexpression via Western blot in MDA-MB-231 and MDA-MB-468 cells (n=3, One-way ANOVA). (F, H, I) Flow cytometry analysis of cell cycle distribution in MDA-MB-231 and MDA-MB-468 cells overexpressing ESCO2 (n=3, unpaired t test). (G, J) Flow cytometry analysis showing the effects of ESCO2 overexpression on apoptosis in MDA-MB-231 and MDA-MB-468 cells (n=3, unpaired t test). (K, L) CCK8 assay showed that ESCO2 overexpression promoted cell proliferation (n=3, Two-way ANOVA). (ns: p > 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Image collected and cropped by CiteAb from the following open publication (https://www.frontiersin.org/articles/10.3389/fonc.2025.1585945/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.